On-Site Therapeutic Drug Monitoring of Paracetamol Analgesic in Non-Invasively Collected Saliva for Personalized Medicine.
Nathalia O Gomes, Paulo A Raymundo-Pereira
https://pubmed.ncbi.nlm.nih.gov/36642790/Actively Recruiting
Led by Cari Health Inc. · Updated on 2025-02-13
30
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are conducting a pilot observational study to develop a minimally invasive wearable Remote Medication Monitor RMM that continuously and in real time measures methadone levels in the interstitial fluid ISF. This study aims to evaluate whether such a device can monitor medication adherence by showing if prescribed methadone doses have been taken. The study involves adults aged 18 to 70 who are prescribed methadone for chronic pain. The study consists of multiple aims involving biosample collection and pharmacokinetic monitoring. In Aim 1, biosamples of ISF and blood will be collected over up to 6 hours to assess if the RMM can detect methadone dose timing using ex vivo methods. Aim 2 involves inserting intradermal microneedle sensors into the skin to continuously monitor methadone levels via the RMM over 6 hours. Later aims include longer monitoring periods of up to 3 days to observe methadone and its metabolites in ISF. Participants will attend up to three visits involving ISF and blood sample collections, wearing the RMM device, and pharmacokinetic monitoring. Researchers will analyze methadone concentrations and metabolite levels using advanced laboratory techniques such as Liquid Chromatography-Mass Spectroscopy. The primary outcomes include correlations between methadone measurements in ISF and blood to evaluate the devices monitoring capabilities. The study is expected to run until April 2026.
CONDITIONS
Assessment of Methadone Dose Taken
F
Foster P Carr, MD
T
Torsten Feibig, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Cari Health Inc.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - Up to 3 hours per visit
Participants have dermal interstitial fluid extracted and analyzed using proteomics and other laboratory techniques over a period of up to 3 hours to characterize the fluid.
1 visit
Duration - Up to 6 hours per visit
Participants undergo biosample collections and pharmacokinetic monitoring over up to 6 consecutive hours to assess methadone concentrations before and after a dose using remote medication monitoring and laboratory analysis.
2 separate visits
Duration - Up to 3 days
Participants wear intradermal microneedle sensing devices continuously on the skin for up to 3 days to assess methadone pharmacokinetics over time with ongoing biosample collections.
1 extended visit with continuous monitoring
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Nathalia O Gomes, Paulo A Raymundo-Pereira
https://pubmed.ncbi.nlm.nih.gov/36642790/Federico Ribet, Annika Bendes, Claudia Fredolini...
https://pubmed.ncbi.nlm.nih.gov/36748807/Mark Friedel, Benjamin Werbovetz, Amy Drexelius...
https://pubmed.ncbi.nlm.nih.gov/37395135/Cari Health Inc.
Lead Sponsor